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Abstract 
A recently discovered series of inhibitors of the ATPase function of bacterial type IIA 
topoisomerases featuring a carboxypyrrole component led us to attempt to replace this group 
with a potentially bioisosteric carboxypyrazole. Accordingly, synthetic pathways to 2-(4-(1H-
pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic acids or 2-(4-(N-methyl-1H-
pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic acids featuring an array of 
substituents on the pyrazole ring were explored. Unfortunately, none of the analogues made 
were effective on the ATPase function of Mycobacterium tuberculosis gyrase, as well on the 
DNA supercoiling activity of the whole gyrase of M. tuberculosis and Escherichia coli. 
However, this work is still providing original insights in chemistry as well as in the structure-
activity relationships of this series of inhibitors. 
 
Résumé 
Une série récente d’inhibiteurs de la fonction ATP-asique des topoisomerases bactériennes de 
type IIA comportant un noyau carboxypyrrole nous a conduits à tenter de remplacer celui-ci 
par un noyau carboxypyrazole bioisostère. Ainsi, des accès aux dérivés d’acide 2-(4-(1H-
pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylique, comportant une gamme de 
substituants, ont été explorés. Malheureusement, aucun des analogues préparés n’a eu d’effet, 
que ce soit sur la fonction ATP-asique de la gyrase de Mycobacterium tuberculosis ou sur 
l’activité de surenroulement des gyrases de M. tuberculosis ou d’Escherichia coli. Toutefois, 
ce travail représente une contribution originale en ce qui concerne la chimie ou les relations 
structure-activité de cette série d’inhibiteurs. 
 
Keywords: ATPase, topoisomerases; antibiotic; bioisosteres; pyrazole 
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Introduction 
In the recent past, the strategies used to find new antibiotics effective on bacterial strains such 
as multiple resistant Mycobacterium tuberculosis, the Gram-positive methicillin-resistant 
strains of Staphylococcus aureus (MRSA), and the vancomycin-resistant Enterococcus spp as 
well as the Gram-negative Actinobacter or Pseudomonas spp. currently plaguing hospitals1 
have undergone many changes. A remarkable report from a major actor in the domain, 
reviewing the results of a full genomic approach, led amongst other conclusions to the 
following statement: “The only way to overcome the challenges of multifactorial antibacterial 
lead optimization is to expand the number of chemical derivatives. We now employ roughly 
two chemists for each biologist in the antibacterial therapeutic area, a fourfold turn-around 
from the days when genomics dominated our activities”.2 The consequence of this has indeed 
led to extensive medicinal chemistry in the recent past, which notably led to the discovery of 
many original series of antibiotics inhibiting bacterial type IIA topoisomerases.3 Amongst 
these, series of pyrrole-containing inhibitors of the ATPase function of bacterial type IIA 
topoisomerases such as the compounds 1a-c depicted in figure 1 were reported.4,5 Extensive 
structure-activity studies led to many analogues including the pyrrolo[2,3-c]pyridine 
derivative 26 or the more elaborated triazole-bearing analogue 3.7 The latter two were actually 
studied for their antimycobacterial effect on a mice model of M. tuberculosis infection.8 
Replacing the carboxypyrrole by a carboxyimidazole group turned out to be possible and 
imidazole derivatives such as  4 were also claimed for their inhibition of DNA gyrase and 
topoisomerase IV as well as their antibacterial effect.9,10 Aside from extensive rescaffolding 
of the central 4-aminopiperidine with other cyclic amines,11-16 the 2-(piperidin-1-yl)thiazole 
component could be replaced, with relative success, by a carboxamide17 or other 
heterocycles18 such as the randomly chosen 4-phenyltriazole 519 and more recently, 
antibacterials such as the tetrahydrobenzo[1,2-d]thiazole 6 were reported.20 Extensive work 
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on the carboxylic acid-bearing component of these series led to compound 7 which featured 
an improved antibacterial activity as well as a lower in vivo clearances and was thus selected 
for clinical trials.21 In view of this, along with our simple method for the preparation of 
carboxypyrazoles,22 we set to prepare the pyrazole-bearing series of compounds 8 and 9 in 
order to determine in this case whether a pyrazole nucleus could also be a bioisostere of the 
carboxy-pyrrole component. 
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Figure 1. Structures of compounds 1-9. 
 
Results and discussion 
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As depicted in scheme 1, the pyrazole acids 11a-d were obtained by hydrolysis of the 
corresponding trifluoromethyl pyrazoles 10a-d, as previously reported22 or described in the 
experimental part. Initially, their coupling with the dihydrochloride salt of amine 12, 
previously described,23 to give amides 13a-d was achieved using a mixture of phosphorus 
oxychloride and pyridine. This unusual method has been successfully applied in the past for 
difficult cases24 including one involving a pyrazole carboxylic acid.25 However, if the modest 
yield obtained could be raised with an excess of the acid and phosphorus oxychloride in some 
cases we realized later on in the course of the preparation of the N-methyl derivatives 9 that 
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) was a far 
better coupling agent. To prepare the trifluoromethyl bearing amide 13e, we used the N-
protected acid 14 (preparation described in the experimental part). Coupling of this acid with 
amine 12 using phosphorus oxychloride and pyridine followed by the cleavage of the 
ethoxyethyl protecting group gave compound 13e in an 18 % overall yield. Hydrolysis of 
esters 13a-e to give the target acids 8a-e was achieved using lithium hydroxide as described 
for the pyrrole series of inhibitors.23 A relatively large scale (200 mg) and a minimal amount 
of water were found necessary to isolate, by precipitation, substantial amount of the rather 
water-soluble acids 8a and 8b. Unfortunately, a complete lack of inhibition effect was 
observed for the analogues 8a-e on disk-based assays for bacterial strains such as E. coli (data 
not shown). Moreover, to remove the possibility of a lack of membrane solubility which 
would have explained these results, compounds 8a-e were also assessed on various bacterial 
gyrases assays. No effect was seen on the DNA supercoiling activity of the whole DNA 
gyrases of M. tuberculosis and E. coli, even at the highest concentration tested (2.5 mM; data 
not shown). 
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Scheme 1: i: NaOH, EtOH/H2O, mw 150 °C. ii: POCl3, pyridine. iii: a) POCl3, pyridine, b) 
H3O
+Cl-, EtOH. iv: LiOH, THF/H2O. 
 
For the synthesis of the N-methylated analogues 9a-j, a different synthetic approach to the 
key intermediate 19 was initially explored. By heating equimolar amount of the N-
methylpyridin-4-amine (15) and the methyl 2-bromothiazole-5-carboxylate (16) in a 
microwave oven at 100 °C for 15 minutes, a close to quantitative yield of the pyridinium salt 
17 was obtained. Treatment of this salt with sodium borohydride in methanol led to a mixture 
of the partially hydrogenated dihydropyridine 18 and a smaller proportion of the target 
piperidine 19, which could not be separated at this stage. Reduction trials with various 
borohydrides did not improve this ratio nor atmospheric palladium-catalyzed hydrogenation 
of the mixture of 18 and 19. In any case, the coupling of these crude amines with pyrazole 
carboxylic acids 11a-c, using the much more efficient TBTU, gave a mixture of the amides 
20a-c and 21a-c from which the pure 3,4-dihydropyridines 20a-c could be isolated in 30-49 
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% yield. The LC/MS monitoring of this reaction actually pointed out the occurrence of 
various pairs of TBTU adducts (i.e.: m/z = 446 and 448 or m/z = 419 and 421, when coupling 
the mixture of 18 and 19 with acid 11a). This led us to add ammonia in the reaction mixture 
to decompose them before the reaction work up. The reduction of the dihydropyridine ring of 
amides 20a-c turned out to be challenging and the only reagents which provided modest 
amount of the reduced compounds 21a-c (22-45 % yield) was the combination of 
triethylsilane and trifluoromethane sulfonic acid. Extensive investigation of the various 
products arising from this ionic-based reduction was made and in the case of compound 20b, 
we could isolated the tricyclic derivative 22. As described below, the bridged structure of this 
compound was fully established by an X-ray crystallography study. The mechanism for the 
occurrence of this compound is quite straightforward, upon protonation of the 3,4-
dihydropyridine double bond of compound 20b, the resulting cation can either be quenched 
by the triethylsilane, to give the reduced amide 21b, or react internally with the nucleophilic 
nitrogen of the pyrazole ring to give 22. Hydrolysis of the methyl ester of compounds 21a-c, 
to give the target analogues 9a-c, was then achieved as above using lithium hydroxide. 
Concerning the 1H NMR characterization of all these N-methylamides, their 1H NMR spectra 
at room temperature pointed out the occurrence of equilibrium between at least two 
conformations. In every cases, as described in the experimental part, when raising the 
temperature to 90 °C, all the 1H NMR signals resolved into a single conformation much easier 
to describe. For the same reason, the 13C NMR spectra obtained at room temperature were 
intractable and no attempts were made to obtain them at 90 °C. 
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Scheme 2: i: MeCN, 100 °C, 15 mn. ii: NaBH4, MeOH. iii: a)TBTU, iPr2EtN, THF, 20 °C, b) 
NH4OH. iv: Et3SiH, CF3SO3H, CH2Cl2, 20°C, 12h. v: LiOH, MeOH, H2O, 20 °C, 12h. 
 
The Ortep-3 diagram26 of compound 22 is shown in Figure 2. The crystallographic data 
collection and refinement parameters are in table 1 in the experimental part. Compound 22 
crystallizes in the triclinic space group P -1, with one molecule in the asymmetric unit. A 
geometric analysis of all bond distances and angles performed by carrying out a Mogul27 
geometry check implemented in the program Mercury28 showed that most bond distances, 
bond angles and torsion angles have typical geometry. Only a couple of valence angles 
(C2_C1_N1 and O4-C2-C1) concerning the pyrazolo-diazepanone bicycle have an absolute 
value of z-score slightly above 4. Two planes may be defined through the heteroatom skeleton 
of the molecule. Plane 1 is formed by the pyrazole ring fused with diazepane ring, which 
adopts a sofa conformation since the C4 is the most distant atom from the mean plane of the 
ring (0.775(2)Å). Plane 2 is formed by the piperidine ring to which is attached, equatorially at 
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the N3 atom, the thiazole ring. Cremer and Pople ring puckering parameters29 (Q = 0.517(2) 
Å, θ = 176.9(2)°, ϕ = 120(5)°) suggest that the piperidine ring is in a chair conformation. The 
dihedral angle between the two planes is 75.7°. 
 
 
 
Figure 2. X-ray based structure of compound 22. 
 
To avoid the difficulties encountered in the reduction of compounds 20a-c, the alternative 
pathway, depicted in scheme 3, was investigated for the preparation of analogues 9d-j. As 
observed by LC/MS, the condensation of N-methylpiperidin-4-amine (20) with the 2-
bromothiazole 13 led to a mixture of the double and mono-substituted products 21 and 16. To 
confirm the reported30 regioselectivity of such N-arylation step in our case, the coupling of the 
crude mixture of 21 and 16 was first undertaken with the 4-chloropyrazole-5-carboxylic acid 
(8c). In this control experiment, amide 18c was thus obtained in a 9 % overall yield from the 
piperidine 20. Despite this rather low yield, because of the simplicity of this pathway, the 
amides 18d-j were then prepared from the corresponding carboxypyrazoles 8d-j (preparations 
described in the experimental part). From these esters, their hydrolysis, using lithium 
hydroxide, gave the target acids 9d-j in 46-75 % yield. Two types of biochemical assays were 
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performed: DNA supercoiling and ATPase activity inhibitions. A very weak inhibition was 
observed using the DNA supercoiling assays (M. tuberculosis as well as E. coli) for 
compound 9b (IC50 = 2 mM) in which moxifloxacin displayed an IC50 of 2.5 µM but no effect 
was observed on the ATPase activity. Unfortunately none of the analogues subsequently 
made had any effect on these two types of biochemical assays. 
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Scheme 3: i: iPr2EtN, MeCN, 100 °C, 2h, MW. ii: a) TBTU, iPr2EtN, THF, 20 °C, b) 
NH4OH. iii: LiOH, MeOH, H2O, 20 °C, 12h. 
 
Conclusion 
This work was an attempt to determine whether a carboxypyrazole could, in the present case, 
be a bioisosteric replacement of a carboxypyrrole. On the chemistry point of view, by using 
the previously disclosed synthesis of compound 12,23 we could couple it with various 
pyrazole carboxylic acids and this led to the analogues 8a-e. To synthesize the N-methylated 
derivatives 9a-j, two synthetic pathways were investigated. The first one used an original 
access to compound 18 and allowed the preparation of analogues 9a-c. However, this path 
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features the drawback of a side reaction leading to bridged products such as the fully 
identified compound 22. To avoid this, a second path was sought and we first established that 
equimolar reaction between the N-methylated piperidine 23 and the 2-bromothiazole 16 does 
provide an access to the key N-methyl intermediate 19 along with the bis-substituted 
compound 24. This path was used to prepare analogues 9d-j which, in view of the lipophilic 
group of most active pyrrole-bearing series depicted in figure 1, were dressed with various 
combination of lipophilic groups on their pyrazole ring. However, the effect of compounds 
9a-j on the whole DNA gyrases assays of M. tuberculosis and E. coli turned out to be 
disappointing. In this regard, the replacement of the lipophilic methyl group of the pyrrole-
bearing antibacterials depicted in figure 1 by a polar nitrogen atom is indeed not favorable. 
Despite this, we hope that this report, which provides some insights in the chemistry of these 
series as well as in their structure-activity relationships, will still be useful to other 
investigators. 
 
Experimental part 
Disk-based assays. The strain used in this study was E. coli CIP 76.24 (susceptible to 
ofloxacin). For routine use, this strain was grown at 37 °C on trypticase soy agar plates 
(BioMérieux, La Balme-Les-Grottes, France). The antimicrobial susceptibility test was 
performed on Mueller-Hinton agar (BioMérieux, La Balme-Les-Grottes, France) by an agar 
diffusion method, according to the guidelines of the Antibiogram Committee of the French 
Society for Microbiology.31 Each compound was solubilized in DMSO to obtain a solution of 
50 mg/ml. The in vitro susceptibility to 5 compounds was tested by the agar dilution method. 
These solubilized compounds were used immediately after dilution. The serial dilutions were 
performed in physiological serum and 10 µL of the dilution were deposited on a blank disk 
(Biorad). A disk without any compound, and another with 10 µl DMSO were added on the 
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plates, as negative controls. All plates were incubated at 37°C for 24h. The strain was fully 
impervious to the compounds 5a-e tested. 
DNA supercoiling assay. The M. tuberculosis DNA gyrase was purified as described 
previously.32 The reaction mixture (total volume, 30 µl) contained DNA gyrase assay buffer 
(40 mM Tris-HCl [pH 7.5], 25 mM KCl, 6 mM magnesium acetate, 2 mM spermidine, 4 mM 
dithiothreitol, bovine serum albumin [0.36 µg/mL], 10 mM potassium glutamate, 1 mM ATP 
[pH 8.0]) and relaxed pBR322 DNA (0.4 µg) as the substrate. Gyrase proteins (180 ng of 
GyrA and 126 ng of GyrB) were mixed in the presence of increasing concentrations of 
quinolones for 1 h at 37°C. Reactions were terminated by the addition of 50 % glycerol 
containing 0.25 % bromophenol blue, and the total reaction mixture was subjected to 
electrophoresis in a 1 % agarose gel in 0.5X TBE (Tris-borate- EDTA, pH 8.3) buffer. After 
electrophoresis for 5.5 h at 50 V, the gel was stained with ethidium bromide (0.7 µg/mL). The 
inhibitory effect of quinolones on DNA gyrase was assessed by determining the concentration 
of drug required to inhibit the supercoiling activity of the enzyme by 50 % (IC50). 
Supercoiling activity was assessed by tracing the brightness of the bands corresponding to the 
supercoiled pBR322 DNA with Molecular Analyst software (Bio-Rad). For the E. coli DNA 
gyrase assay, a similar protocol was used with a commercial available (John Innes Enterprises 
Ltd) recombinant enzyme. 
DNA gyrase ATPase assay. The M. tuberculosis DNA gyrase ATPase domain was purified 
as described previously.33 The ADP-GloTM kinase assay (Promega, Madison, WI) was used to 
test the ATPase inhibition of the compounds having IC50 values for supercoiling inhibition 
below or equal to 2 mM. The ATPase assay was carried out in a 384-well plate with a 5 µL 
volume containing 0.7 µl of 40 g/l M. tuberculosis ATPase, 1 µL Reaction Buffer (Tris 40 
mM (pH = 7.5), MgCl2 20 mM, KCl 50 mM, BSA 0.1 mg/mL) and 0.5 µl ultra pure ATP 1 
mM. Reactions in each well were started by adding the ATP solution and kept going for an 
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hour at 20°C. Then 5 µl of ADP-Glo reagent was added into each well to stop the reaction and 
consume the remaining ADP within 40 minutes. At the end, 10 µL of the kinase detection 
reagent was added into the well and incubated for 1 hour and then the luminescence was 
monitored. Note: the novobiocin used as a reference in this assay had an IC50 of 1 µM. 
X-ray analysis. X-ray data were collected at 293 K using CuKα (1.54187 Å) on a Rigaku 
mm007 HF rotating anode diffractometer equipped with Osmic CMF mirror and a curved 
imaging-plate RapidII detector. The Rigaku CrystalClear-SM Expert 2.0 r15 software 
package34 was used for data collection and data reduction. The data were corrected semi-
empirically for absorption using multi-scan approach through the Fs Process scaling 
algorithm. The structure was solved by direct methods using SHELXS-9735 and refined by 
full-matrix least squares on F2 using SHELXL-2014/7.36 All non-hydrogen atoms were 
successfully refined using anisotropic displacement parameters. Hydrogen atoms were found 
in the Fourier difference synthesis and fixed. Crystallographic data for the structure of 
compound 22 were deposited in the Cambridge Crystallographic Data Centre, with number 
CCDC 1049028. 
 
Table 1. Crystal data and structure refinement for 
compound 22 
Empirical formula  C17H21N5O4S 
Formula weight  391.45 
Temperature  293(2) K 
Wavelength  1.54187 Å 
Crystal system, Space 
group  
Triclinic, P-1 
Unit cell dimensions a = 8.8695(2) Å 
a= 113.309(8)° 
b = 10.7315(3) Å 
b= 98.373(7)° 
c = 10.8733(7) Å 
g = 96.812(7)° 
Volume 922.50(9) Å3 
Z, Calculated Density 2, 1.409 mg/m3 
Absorption coefficient 1.863 mm-1 
F(000) 412 
Crystal size 0.380 x 0.340 x 0.270 mm3 
Theta range for data 
collection 
4.530 to 68.248°. 
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Index ranges -10 ≤ h ≤ 10, -12 ≤ k ≤ 12 
-13 ≤ l ≤ 13 
Reflections collected 12730 
Independent reflections 3283 [R(int) = 0.0301] 
Completeness to theta = 
67.687° 
96.7 %  
Absorption correction Semi-empirical from 
equivalents 
Max. and min. 
transmission 
0.61 and 0.47 
Refinement method Full-matrix least-squares 
on F2 
Data / restraints / 
parameters 
3262 / 0 / 247 
Goodness-of-fit on F2 1.075 
Final R indices [I>2σ(I)] R1 = 0.0416,  
wR2 = 0.1101 
R indices (all data) R1 = 0.0527,  
wR2 = 0.1199 
Largest diff. peak and hole 0.217 and -0.174 e.Å-3 
 
Chemistry. A Biotage initiator 2 microwave oven was used for reactions mentioning such 
heating method. 1H NMR and 13C NMR spectra were recorded on a Bruker Avance 400 
spectrometer at 400 MHz and 100 MHz, respectively. Shifts (δ) are given in ppm with respect 
to the TMS signal and cross-coupling constants (J) are given in hertz. Column 
chromatography were performed either on Merck silica gel 60 (0.035 - 0.070 mm) or neutral 
alumina using a solvent pump and an automated collecting system driven by a UV detector 
set to 254 nm unless required otherwise. Sample deposition was carried out by adsorption of 
the mixture to be purified on a small amount of the solid phase followed by its deposition on 
the top of the column. The low resolution mass spectra were obtained on an Agilent 1100 
series LC/MSD system using an atmospheric electrospray ionization system and the high 
resolution mass spectra (HRMS) were obtained using a Waters Micromass Q-Tof with an 
electrospray ion source. Unless stated otherwise, a purity of at least 95 % was obtained for all 
the compounds by means of chromatography, recrystallization or distillation and this level of 
purity was established by TLC, LC/MS and NMR spectroscopy. Moxifloxacin, used as active 
compound for the supercoiling assays, was provided by Bayer Pharma, Puteaux, France. 
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General procedure for the hydrolysis of trifluoromethylpyrazole into pyrazole-5-
carboxylic acid 
As previously described for other cases,22 in a Biotage tube, the relevant 
trifluoromethylpyrazole (1 mmol) and sodium hydroxide (0.2 g, 5 mmol) were stirred in 
ethanol/water 1:3 (1.2 mL). The tube was sealed and heated at 150 °C for 1 h in a microwave 
oven. The resulting suspension was dissolved in water; the aqueous phase was washed with 
dichloromethane twice and made acidic with 2N hydrochloric acid. This was extracted with 
ethyl acetate twice; the organic layer were combined and washed with brine, dried over 
magnesium sulfate, and concentrated to dryness to yield the corresponding acid as described 
below. CAUTION: the reaction leads to the release of fluorine ions which attack the glass 
tubes. Never recycle the reaction tubes as their resistance toward pressure and temperature 
may have been weakened in the process. 
4-Chloro-3-ethoxy-1H-pyrazole-5-carboxylic acid (11d): Step 1, preparation of 4-chloro-3-
ethoxy-5-(trifluoromethyl)-1H-pyrazole (10d): In ethanol (50 mL), 3-ethoxy-5-
(trifluoromethyl)-1H-pyrazole (1.42 g, 7.89 mmol)37 and N-chlorosuccinimide (1.26 g, 9.46 
mmol) were stirred overnight at room temperature and then heated to reflux for 90 minutes. 
This was concentrated to dryness, the residue was dispersed in cyclohexane and filtrated. The 
filtrate was washed with water, dried over magnesium sulfate and concentrated to dryness to 
yield the 4-chloropyrazole which NMR spectra feature two detectable tautomers. 1H NMR 
(CDCl3): major tautomer, 1.35 (t, 3H, J = 7.0 Hz); 4.35 (q, 2H, J = 7.0 Hz); 10.26 (s(br), 1H); 
minor tautomer, 1.45 (t, 3H, J = 7.0 Hz); 4.56 (q, 2H, J = 7.0 Hz); 10.12 (s(br), 1H). 13C 
NMR (CDCl3, D1 set at 5 s): major tautomer, 14.6; 69.9; 97.7; 119.0 (J = 270 Hz); 132.3 (J = 
39 Hz); 157.2; minor tautomer, 18.0; 58.5; 66.0; 117.9 (J = 274 Hz); 145.3 (J = 39 Hz); 
166.8. HRMS: calcd for C6H7ClF3N2O + H: 215.0199; found: 215.0135. Step 2, the 
hydrolysis procedure described above was applied to this compound and led to the acid 11d 
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as a beige power (0.66 g, 67 %). 1H NMR (DMSO-d6): 1.31 (t, 3H, J = 7.0 Hz); 4.23 (q, 2H, 
J = 7.0 Hz); 13.2 (s(br), 2H). 13C NMR (DMSO-d6, D1 set at 5 s): 13.0; 65.3; 97.0; 130.9; 
158.7; 159.6. HRMS: calcd for C6H7ClN2O3 - H: 189.0067; found: 189.0066. 
3-propoxy-1H-pyrazole-5-carboxylic acid (11e): Step 1, preparation of 3-propoxy-5-
(trifluoromethyl)-1H-pyrazole: In dimethylformamide (100 mL, dried over 4A molecular 
sieve), 5-(trifluoromethyl)-1H-pyrazol-3-ol38 (4.04 g, 0.026 mol), cesium carbonate (9.52 g, 
0.029 mol) and propyliodide (4.51 g, 0.026 mol) were heated at 80 °C under a moisture-
protected atmosphere for 14 hours. This was concentrated to dryness, the residue was 
dispersed in water and ethyl acetate, the organic layer was washed with water, brine, dried 
over magnesium sulfate and concentrated. The residue was purified by a chromatography over 
silica gel (cyclohexane – dichloromethane from 1/2 to 0/1) to yield the 3-propoxy-5-
(trifluoromethyl)-1H-pyrazole as a volatile oil (2.72 g, 52 %). 1H NMR (CDCl3): 1.04 (t, 3H, 
J = 7.5 Hz); 1.83 (m, 2H); 4.07 (t, 2H, J = 6.5 Hz); 5.87 (s, 1H); 9.69 (s(br), 1H). 13C NMR 
(CDCl3): 10.1; 22.3; 73.2; 85.1; 120.5 (J = 270 Hz); 140.7 (J = 39 Hz); 158.4. HRMS: calcd 
for C7H9F3N2O + H: 195.0745; found: 195.0715. Step 2: the hydrolysis procedure described 
above was applied to this compound and led to the acid 11e (0.64 g, 85 %). 1H NMR (DMSO-
d6): 0.94 (t, 3H, J = 7.3 Hz); 1.69 (m, 2H); 4.01 (t, 2H, J = 6.7 Hz); 6.14 (s, 1H); 12.96 (s(br), 
2H). 13C NMR (DMSO-d6, D1 set at 5 s): 10.2; 21.9; 70.4; 91.9; 135.3; 160.5; 162.4. HRMS: 
calcd for C7H10N2O3 + H: 171.0957; found: 171.0770. 
3-butoxy-1H-pyrazole-5-carboxylic acid (11f): Step 1, preparation of 3-butoxy-5-
(trifluoromethyl)-1H-pyrazole: In dimethylformamide (100 mL, dried over 4A molecular 
sieve), 5-(trifluoromethyl)-1H-pyrazol-3-ol38 (4.06 g, 0.026 mol), cesium carbonate (9.56 g, 
0.029 mol) and butylbromide (3.65 g, 0.026 mol) were heated at 80 °C under a moisture-
protected atmosphere for 14 hours. This was concentrated to dryness, the residue was 
dispersed in water and ethyl acetate, the organic layer was washed with water, brine, dried 
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over magnesium sulfate and concentrated. The residue was purified by a chromatography over 
silica gel (cyclohexane – dichloromethane from 4/1 to 0/1) to yield the 3- butoxy-5-
(trifluoromethyl)-1H-pyrazole as a volatile oil (2.19 g, 39 %). 1H NMR (CDCl3): 0.98 (t, 3H, 
J = 7.4 Hz); 1.48 (m, 2H); 1.78 (m, 2H); 4.11 (t, 2H, J = 6.5 Hz); 5.86 (s, 1H); 10.32 (s(br), 
1H). 13C NMR (CDCl3): 13.6; 18.9; 30.9; 71.5; 85.0; 120.7 (J = 269 Hz); 140.7 (J = 39 Hz); 
158.4. HRMS: calcd for C8H11F3N2O + H: 209.0902; found: 209.0817. Step 2: the hydrolysis 
procedure described above was applied to this compound and led to the acid 11f (0.86 g, 90 
%). 1H NMR (DMSO-d6): 0.91 (t, 3H, J = 7.3 Hz); 1.40 (m, 2H); 1.66 (m, 2H); 4.05 (t, 2H, J 
= 6.5 Hz); 6.13 (s, 1H); 13.01 (s(br), 2H). 13C NMR (DMSO-d6, D1 set at 5 s): 13.6; 18.6; 
30.7; 68.6; 91.9; 135.2; 160.5; 162.4. HRMS: calcd for C8H12N2O3 + H: 185.0926; found: 
185.0884. 
3-isopropoxy-1H-pyrazole-5-carboxylic acid (11g): Step 1, preparation of 3-isopropoxy-5-
(trifluoromethyl)-1H-pyrazole: In dimethylformamide (100 mL, dried over 4A molecular 
sieve), 5-(trifluoromethyl)-1H-pyrazol-3-ol38 (5.28 g, 0.034 mol), cesium carbonate (12.4 g, 
0.038 mol) and isopropylbromide (4.27 g, 0.034 mol) were heated at 80 °C under a moisture-
protected atmosphere for 14 hours. This was concentrated to dryness, the residue was 
dispersed in water and ethyl acetate, the organic layer was washed with water, brine, dried 
over magnesium sulfate and concentrated. The residue was purified by a chromatography over 
silica gel (dichloromethane) to yield the 3-isopropoxy-5-(trifluoromethyl)-1H-pyrazole as a 
volatile oil (3.59 g, 53 %). 1H NMR (CDCl3): 1.38 (d, 6H, J = 6.1 Hz); 4.50 (sept, 1H, J = 6.1 
Hz); 5.54 (s, 1H); 11.13 (s(br), 1H). 13C NMR (CDCl3): 21.7; 75.2; 85.3; 120.7 (J = 267 Hz); 
141.0 (J = 39 Hz); 157.0. HRMS: calcd for C7H9F3N2O + H: 195.0745; found: 195.0665. Step 
2: the hydrolysis procedure described above was applied to this compound and led to the acid 
11g (0.75 g, 87 %). 1H NMR (DMSO-d6): 1.25 (d, 6H, J = 6.1 Hz); 4.64 (sept, 1H, J = 6.1 
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Hz); 6.11 (s, 1H); 12.98 (s(br), 2H). 13C NMR (DMSO-d6, D1 set at 5 s): 22.3; 72.0; 93.1; 
135.8; 161.0; 161.9. HRMS: calcd for C7H10N2O3 + H: 171.0770; found: 171.0740. 
3-(pentan-3-yloxy)-1H-pyrazole-5-carboxylic acid (11h): Step 1, preparation of 3-(pentan-3-
yloxy)-5-(trifluoromethyl)-1H-pyrazole: In dimethylformamide (100 mL, dried over 4A 
molecular sieve), 5-(trifluoromethyl)-1H-pyrazol-3-ol38 (4.11 g, 0.027 mol), cesium carbonate 
(9.6 g, 0.029 mol) and 3-bromopentane (4.08 g, 0.027 mol) were heated at 80 °C under a 
moisture-protected atmosphere for 14 hours. This was concentrated to dryness, the residue 
was dispersed in water and ethyl acetate, the organic layer was washed with water, brine, 
dried over magnesium sulfate and concentrated. The residue was purified by a 
chromatography over silica gel (cyclohexane – dichloromethane 1/2 to 0/1) to yield the 3-
(pentan-3-yloxy)-5-(trifluoromethyl)-1H-pyrazole as a volatile oil (2.54 g, 42 %). 1H NMR 
(CDCl3): 0.98 (t, 6H, J = 7.4 Hz); 1.73 (m, 4H); 4.11 (pent, 1H, J = 5.8 Hz); 5.82 (s, 1H); 8.63 
(s(br), 1H). 13C NMR (CDCl3): 9.3; 26.0; 84.9; 85.7; 120.8 (J = 268 Hz); 141.3 (J = 38 Hz); 
157.7. HRMS: calcd for C9H13F3N2O + H: 223.1058; found: 223.0955. Step 2: the hydrolysis 
procedure described above was applied to this compound and led to the acid 11h (0.82 g, 96 
%). 1H NMR (DMSO-d6): 1.00 (t, 6H, J = 7.5 Hz); 1.74 (m, 4H); 4.31 (pent, 1H, J = 5.8 Hz); 
6.30 (s, 1H); 11.90 (s(br), 2H). 13C NMR (DMSO-d6, D1 set at 5 s): 9.4; 21.1; 83.7; 93.9; 
135.3; 161.8; 162.7. HRMS: calcd for C9H14N2O3 + H: 199.1083; found: 199.1042. 
4-Bromo-3-methyl-1H-pyrazole-5-carboxylic acid (11i): This compound was obtained from 
4-bromo-3-methyl-5-(trifluoromethyl)-1H-pyrazole39 using the procedure described above as 
a white power (0.82 g, 88 %). 1H NMR (DMSO-d6): 2.20 (s, 3H); 13.34 (s(br), 2H). 13C 
NMR (DMSO-d6, D1 set at 5s): 11.0; 95.8; 137.5 (br); 143.6 (br); 161.7. HRMS: calcd for 
C5H5BrN2O2 - H: 202.9456; found: 202.9473. 
Synthesis of 4-bromo-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid (11j). This 
compound was obtained using a previously described procedure.40 A solution of 4-bromo-3-
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methyl-5-(trifluoromethyl)-1H-pyrazole39 (0.98 g, 4.27 mmol), potassium permanganate (1.7 
g, 10.69 mmol) in water/tertbutanol 5-1 (60 mL) was stirred at 75 °C for three days. The 
suspension was filtered, the filtrate made acid using 37 % hydrochloric acid, the resulting 
precipitate was filtered and dissolved in a 1N sodium hydroxide solution. This aqueous layer 
was washed with dichloromethane twice, and made acid again using 37 % hydrochloric acid. 
This was extracted with ethyl acetate, the organic layer was washed with brine, dried over 
magnesium sulfate and concentrated to dryness to yield compound 11j as a white powder 
(0.64 g, 57 %). 1H NMR (DMSO-d6): 14.18 (s(br), H); 14.99 (s(br), H). 13C NMR (DMSO-
d6, D1 set at 5s): 95.2; 121.0 (270 Hz); 135.0; 140.7 (37 Hz); 159.1. HRMS: calcd for 
C5H2F3BrN2O2 - H: 258.9153; found: 258.9208. 
General preparation of amides 13a-d, representative synthesis of methyl 2-(4-(1H-
pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylate (13a). A calcium chloride-
protected solution of methyl 2-(4-aminopiperidin-1-yl)thiazole-5-carboxylate dihydrochloride 
dihydrate (12)23 (400 mg, 1.14 mmol) and 1H-pyrazole-4-carboxylic acid (11a) (380 mg, 3.38 
mmol) in pyridine (9 mL) was cooled to -15 °C. Phosphorus oxychloride (537 mg, 3.50 
mmol) was then slowly added and the solution stirred at -15 °C for 15 min. This was warmed 
to 50 °C few seconds then cooled back to 0 °C before adding an excess of a saturated solution 
of sodium hydrogen carbonate. The mixture was extracted four times with ethyl acetate, the 
organic layers were combined and washed once with brine, dried over magnesium sulfate and 
concentrated to dryness. The crude residue was purified by chromatography over silica gel 
(dichloromethane - ethanol, from 97/3 to 95/5) to yield product 13a as a white solid (240 mg, 
63 %). 1H NMR (DMSO-d6): note: at high concentration, a minor conformer can also be 
observed, 1.67 (m, 2H); 1.87 (m, 2H); 3.25 (m, 2H); 3.76 (s, 3H); 3.99 (m, 2H); 4.01 (m, 1H); 
6.64 (m, 1H); 7.80 (m, 1H); 7.86 (s, 1H); 8.02 (d, 1H, J = 8.2 Hz); 13.20 (s, 1H). 13C NMR 
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(DMSO-d6): 30.4; 45.2; 47.4; 51.6; 105.0; 114.9; 129.8; 146.6; 148.4; 161.1; 161.6; 173.7. 
HRMS: calcd for C14H17N5O3S + H: 336.1130; found: 336.1112. 
Methyl 2-(4-(3-ethoxy-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylate 
(13b): By using the procedure described above, this compound was obtained as a white solid 
(70 mg, 32 %). 1H NMR (CDCl3): 1.41 (t, 3H, J = 7.0 Hz); 1.66 (m, 2H); 2.15 (m, 2H); 3.29 
(m, 2H); 3.84 (s, 3H); 4.10 (m, 2H); 4.20 (q, 2H, J = 7.0 Hz); 4.23 (m, 1H); 6.03 (s, 1H); 6.50 
(s(br), 1H); 7.88 (s, 1H). 13C NMR (CDCl3): 15.2; 30.8; 45.9; 47.7; 52.2; 64.7; 89.8; 115.6; 
137.7; 148.8; 158.4; 162.1; 163.0; 174.2. LC/MS, m/z = 380 (M+H). 
Methyl 2-(4-(4-chloro-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylate 
(13c): By using the procedure described above, this compound was obtained as a white solid 
(150 mg, 49 %). 1H NMR (DMSO-d6): 1.67 (m, 2H); 1.88 (m, 2H); 3.28 (m, 2H); 3.75 (s, 
3H); 3.99 (m, 2H); 4.07 (m, 1H); 7.86 (s, 1H); 8.04 (m, 2H); 13.51 (s, 1H). 13C NMR 
(DMSO-d6): 30.8; 45.7; 47.8; 52.2; 109.3; 115.5; 129.8; 141.6; 148.9; 160.5; 162.1; 174.2. 
HRMS: calcd for C14H16ClN5O3S + H: 370.0741; found: 370.0757. 
Methyl 2-(4-(4-chloro-3-ethoxy-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylate (13d): By using the procedure described above, this compound was obtained as a 
white solid (60 mg, 4 %). 1H NMR (DMSO-d6): 1.32 (t, 2H, J = 7.0 Hz); 1.65 (m, 2H); 1.93 
(m, 2H); 3.33 (m, 3H); 3.75 (s, 3H); 3.96 (m, 2H); 4.08 (m, 1H); 4.23 (q, 2H, J = 7.0 Hz); 
7.87 (m, 2H); 12.91 (s, 1H). 13C NMR (DMSO-d6): 15.1; 30.5; 46.1; 47.4; 52.2; 65.3; 93.7; 
115.6; 134.4; 148.8; 157.5; 158.2; 162.1; 174.2. HRMS: calcd for C16H20ClN5O4S + H: 
414.1003; found: 414.0985. 
1-(1-Ethoxyethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid (14): Step 1, 
preparation of 3-(trifluoromethyl)-1H-pyrazole. Ethoxyethene (19.3 g, 0.267 mol) was 
dissolved in pentane (120 mL). This was cooled to 0 °C with an ice bath and trifluoroacetic 
anhydride (37.6 mL, 0.270 mol) was added slowly. This was stirred overnight at 0 °C and 
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then stirred 3 more hours at room temperature to yield a solution of 4-ethoxy-1,1,1-
trifluorobut-3-en-2-one which was directly used in the next step. Nota as previously 
described,41 the use of pentane was really optimal for this step. To this pentane solution was 
added ethanol (100 mL) and this was cooled to 0°C with a large ice bath. Hydrazine hydrate 
(15.6 mL, 0.321 mol) was slowly added and after an additional 30 minutes of stirring at room 
temperature, the solution was concentrated to dryness. The residue was dissolved in ethyl 
acetate and a saturated solution of sodium hydrogen carbonate. The organic layer was washed 
with a saturated solution of sodium hydrogen carbonate, brine, dried over magnesium sulfate 
and concentrated to dryness. A distillation at 30 mbar in the rotary evaporator heating with a 
heat gun and trapping the distillate in a “no return” bulb gave 3-(trifluoromethyl)-1H-pyrazole 
as a white solid (27.63 g, 75 %). 1H NMR (CDCl3): 6.68 (d, 1H, J = 2.2 Hz); 7.73 (m, 1H); 
12.85 (s(br), 1H). Step 2, preparation of 1-(1-ethoxyethyl)-3-(trifluoromethyl)-1H-pyrazole: 
3-(trifluoromethyl)-1H-pyrazole (1.02 g, 7.50 mmol), ethoxyethene (1.58 g, 21.91 mmol), and 
pyridinium paratoluenesulfonic acid salt (36 mg, 0.14 mmol) were stirred at room temperature 
in dichloromethane (30 mL) for 30 min. The mixture was extracted with dichloromethane, the 
organic layers were combined and washed with water, brine, and then dried over magnesium 
sulfate and concentrated to dryness to yield the N-protected pyrazole as a yellow liquid (770 
mg, 49 %) which was used without further purification. 1H NMR (CDCl3): 1.18 (t, 3H, J = 
7.0 Hz); 1.68 (d, 3H; J = 6.0 Hz); 3.37 (m, 1H); 3.51 (m, 1H); 5.59 (q, 1H, J = 6.0 Hz); 6.61 
(d, 1H, J = 2.4 Hz); 7.67 (m, 1H). Step 3, preparation of 1-(1-ethoxyethyl)-3-
(trifluoromethyl)-1H-pyrazole-5-carboxylic acid (14). To a solution of 1-(1-ethoxyethyl)-3-
(trifluoromethyl)-1H-pyrazole (770 mg, 3.70 mmol) in dry tetrahydrofuran (50 mL) at -78 °C 
under an atmosphere of argon was slowly added n-butyl lithium 2M (2.3 mL, 4.60 mmol). 
This was stirred for 10 minutes and the orange mixture was poured on dry ice dispersed in 
ether. This was allowed to warm to room temperature and the organic layer was extracted 
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with water. The aqueous layer was made acidic with 2N hydrochloric acid and extracted with 
ethyl acetate. The resulting organic layer was washed with water, dried over magnesium 
sulfate and concentrated to dryness to yield compound 14 as a brown oil (540 mg, 58 %) 
which was used without further purification. 
Methyl 2-(4-(3-(trifluoromethyl)-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylate (13e): A calcium chloride protected solution of methyl 2-(4-aminopiperidin-1-
yl)thiazole-5-carboxylate dihydrochloride dihydrate (12)23 (450 mg, 1.30 mmol) and 1-(1-
ethoxyethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid (14) (420 mg, 1.65 mmol) in 
pyridine (14 mL) was cooled to -15 °C. Phosphorus oxychloride (0.51 mL, 5.56 mmol) was 
then slowly added and the solution stirred at -15 °C for 15 min. This was warmed to 50 °C 
few seconds then cooled back to 0 °C before adding an excess of a solution of saturated 
sodium hydrogenocarbonate. The mixture was extracted four times with ethyl acetate, the 
organic layers were combined and washed once with brine, dried over magnesium sulfate and 
concentrated to dryness. The resulting crude residue was treated with hydrochloric acid 2M (5 
mL) in ethanol (4 mL) at room temperature overnight. The yellow solution was extracted with 
ethyl acetate, the organic layer washed with water, brine, dried over magnesium sulfate and 
concentrated to dryness. The residue was purified by chromatography over silica gel 
(dichloromethane - ethanol, from 99/1 to 97/3) to yield compound 13e as a pale yellow solid 
(94 mg, 18 %). 1H NMR (DMSO-d6): 1.60 (m, 2H); 1.95 (m, 2H); 3.33 (m, 2H); 3.75 (s, 3H); 
3.99 (d, 2H); 4.12 (m, 1H); 7.31 (s, 1H); 7.87 (s, 1H); 8.49 (m, 1H); 14.43 (s(br), 1H). 13C 
NMR (DMSO-d6): 30.1; 45.6; 47.1; 54.8; 103.5; 115.1; 121.3 (q, J = 267 Hz); 138.8; 141.1 
(q, J = 39 Hz); 148.3; 157.0; 161.6; 173.7. HRMS: calcd for C15H16F3N5O3S + H: 404.1004; 
found: 404.0940. 
Preparation of acids 8a-e, representative synthesis of 2-(4-(1H-pyrazole-5-
carboxamido)piperidin-1-yl)thiazole-5-carboxylic acid (8a): To a solution of methyl 2-(4-
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(1H-pyrazole-3-carboxamido)piperidin-1-yl)thiazole-5-carboxylate (13a) (187 mg, 0.56 
mmol) in tetrahydrofuran (20 mL) was added a solution of lithium hydroxide (59 mg, 2.46 
mmol) in water (6 mL). The mixture was stirred at room temperature overnight. The solvent 
was removed under vacuum. The mixture was then diluted in water and the aqueous layer 
washed with ether. Hydrochloric acid 2N was added to the aqueous layer added until pH 3, 
which was then concentrated under vacuum (water pump) at room temperature. The residue 
was taken up in water and concentrated under vacuum again. This step was repeated three 
times. The residue was then suspended in a small amount of water at 4 °C and this was 
filtered, washed with cold water (4 °C) and dried under vacuum to yield the desired product 
(8a) as a white powder (110 mg, 61 %). 1H NMR (DMSO-d6): 1.67 (m, 2H); 1.88 (m, 2H); 
3.25 (m, 2H); 3.98 (d, 2H); 4.08 (m, 1H); 6.68 (d, 1H, J = 2.2 Hz); 7.74 (d, 1H, J = 2.2 Hz); 
7.77 (s, 1H); 8.06 (d, 1H, J = 8.1 Hz); 12.94 (s, 2H). 13C NMR (DMSO-d6): 30.9; 45.8; 47.8; 
105.5; 117.3; 132.2; 145.3; 148.2; 161.0; 163.1; 174.0. HRMS: calcd for C13H15N5O3S - H: 
320.0817; found: 320.0852. 
2-(4-(3-Ethoxy-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic acid (8b): 
By using the procedure described above, this compound was obtained as a solid (21 mg, 32 
%). 1H NMR (DMSO-d6): 1.29 (t, 3H, J = 7.0 Hz); 1.58 (m, 2H); 1.90 (m, 2H); 3.27 (m, 2H); 
3.98 (m, 2H); 4.07 (m, 1H); 4.10 (q, 2H, J = 7.0 Hz); 6.21 (s, 1H); 7.78 (s, 1H); 8.15 (d, 1H, J 
= 8.1 Hz); 12.62 (s, 1H). 13C NMR (DMSO-d6): (one signal missing); 15.1; 30.8; 45.9; 47.7; 
65.1; 89.15; 117.5; 148.1; 158.9; 162.2; 163.1; 174.0. HRMS: calcd for C15H19N5O4S - H: 
364.1096; found: 364.1080. 
2-(4-(4-Chloro-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic acid (8c): 
By using the procedure described above, this compound was obtained as a solid (107 mg, 14 
%). 1H NMR (DMSO-d6): 1.67 (m, 2H); 1.88 (m, 2H); 3.25 (m, 2H); 3.97 (d, 2H); 4.06 (m, 
1H); 7.77 (s, 1H); 8.02 (s, 1H); 8.09 (d, 1H, J = 8.1 Hz); 12.67 (s, 1H); 13.50 (s, 1H). 13C 
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NMR (DMSO-d6): 30.2; 45.3; 47.2; 108.8; 116.8; 130.0; 141.1; 147.7; 159.7; 162.6; 173.5. 
HRMS: calcd for C13H14ClN5O3S - H: 354.0461; found: 354.0428. 
2-(4-(4-Chloro-3-ethoxy-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic 
acid (8d): By using the procedure described above, this compound was obtained as a solid (48 
mg, 71 %). 1H NMR (DMSO-d6): 1.32 (t, 3H, J = 7.0 Hz); 1.65 (m, 2H); 1.93 (m, 2H); 3.31 
(m, 2H); 3.95 (m, 2H); 4.08 (m, 1H); 4.23 (q, 2H, J = 7.0 Hz); 7.77 (s, 1H); 7.89 (d, 1H, J = 
8.1 Hz); 12.90 (s, 1H). 13C NMR (DMSO-d6): 14.6; 30.0; 45.7; 46.6; 64.9; 93.1; 116.9; 
134.1; 147.6; 157.1; 157.8; 162.6; 173.5. HRMS: calcd for C15H18ClN5O4S - H: 398.0707; 
found: 398.0690. 
2-(4-(3-(Trifluoromethyl)-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic 
acid (8e): By using the procedure described above, this compound was obtained as a solid (92 
mg, 79 %). 1H NMR (DMSO-d6): 1.60 (m, 2H); 1.95 (m, 2H); 3.30 (m, 2H); 3.99 (m, 2H); 
4.11 (m, 1H); 7.31 (s, 1H); 7.78 (s, 1H); 8.49 (d, 1H, J = 8.1 Hz); 12.64 (s, 1H); 14.44 (s, 
1H). 13C NMR (DMSO-d6): 30.7; 46.2; 47.5; 104.0; 117.6; 121.3 (q, J = 267 Hz); 139.4; 
141.6 (q, J = 38 Hz); 158.1; 157.5; 163.1; 174.0. HRMS: calcd for C14H14F3N5O3S - H: 
388.0728; found: 388.0691. 
Preparation of 1-(5-(methoxycarbonyl)thiazol-2-yl)-4-(methylamino)pyridinium bromide 
(17): In a vial adapted for microwave heating, N-methylpyridin-4-amine (15) (1.04 g, 9.6 
mmol) and methyl 2-bromothiazole-5-carboxylate (16) (2.14 g, 9.6 mmol) were dissolved in 
dry acetonitrile (15 mL, dried over 4Å molecular sieve). This was heated in a microwave 
oven for 15 minutes at 100 °C. The resulting suspension was dissolved in methanol and 
concentrated to dryness to give a brown powder (3.16 g) still containing solvents which was 
used without further purification in the next step. 1H NMR (DMSO-d6): Major tautomer: 3.06 
(s, 3H); 3.91 (s, 3H); 7.1 (m, 1H); 7.20 (m, 1H); 8.40 (s, 1H); 8.76 (m, 1H); 8.89 (m, 1H); 
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10.02 (s, 1H). 13C NMR (DMSO-d6): 30.3; 53.0; 106.45; 111.1; 128.4; 138.2; 140.4; 146.6; 
159.4; 160.9; 164.6. HRMS: calcd for C11H12N3O2S
+: 250.0589; found: 250.0650. 
Preparation of the mixture of methyl 2-(4-(methylamino)-3,4-dihydropyridin-1(2H)-
yl)thiazole-5-carboxylate (18) and methyl 2-(4-(methylamino)piperidin-1-yl)thiazole-5-
carboxylate (19): The crude compound 17 (3.16 g) was dissolved in methanol (100 mL) and 
sodium borohydride (2.39 g, 63.2 mmol) was added portion-wise. The resulting solution was 
stirred for 30 minutes at room temperature, concentrated to dryness and the residue dispersed 
in water. The aqueous layer was saturated with sodium chloride and extracted four times with 
ethyl acetate. The organic layers were combined and washed with brine, dried over 
magnesium sulfate and concentrated to dryness to yield an orange glass (1.89 g, 59 % from 
compound 15). As seen by 1H NMR and LC/MS, this solid contained a 5/1 ratio of 
compounds 18 and 19, and this was used in the next step without further purification. 1H 
NMR (CDCl3): minor compound 19 1.50 (m, 2H); 1.91 (m, 2H); 2.04 (m, 2H); 2.49 (s, 3H); 
3.21 (m, 2H); 3.84 (s, 3H); 4.03 (m, 1H); 7.87 (s, 1H); major compound 18 1.92 (m, 1H); 2.07 
(m, 1H); 2.51 (s, 3H); 3.29 (m, 1H); 3.78 (m, 2H); 3.86 (s, 3H); 5.17 (m, 1H); 6.90 (m, 1H); 
7.93 (s, 1H). LC/MS, main peak at m/z = 223 (M - CH3NH) and secondary peak at m/z = 256 
(M + H). 
Preparation of the dihydropyridine amides 20a-c, representative synthesis of methyl 2-(4-
(N-methyl-1H-pyrazole-3-carboxamido)-3,4-dihydropyridin-1(2H)-yl)thiazole-5-carboxylate 
(17a): Under an argon atmosphere, the mixture of compound 18 and 19 (0.57 g, 2.24 mmol), 
1H-pyrazole-3-carboxylic acid (11a) (0.25 g, 2.2 mmol) and O-(benzotriazol-1-yl)-N,N,N',N'-
tetramethyluronium tetrafluoroborate (TBTU) (1.51 g, 4.7 mmol) were dispersed in 
tetrahydrofuran (50 mL, dried over 4Å molecular sieves). Diisopropylethylamine (1.60 mL, 
9.4 mmol) was added and the suspension was stirred at room temperature for four hours. 
Concentrated ammonia (10 mL, 22 %) was added and this was stirred at room temperature for 
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30 minutes before removing the tetrahydrofuran under vacuum. The residue was diluted in 
ethyl acetate and a saturated solution of sodium hydrogen carbonate. The organic layer was 
washed with a saturated solution of sodium hydrogen carbonate, brine, dried over magnesium 
sulfate and concentrated to dryness. The residue was purified by a chromatography over silica 
gel (dichloromethane – ethanol 95/5) to yield compound 20a as a hard foam (0.38 g, 49 %), a 
sample was recrystallized in toluene. 1H NMR (DMSO-d6 at 90 °C): 2.15 (m, 2H); 3.01 (s, 
3H); 3.7 (m, 1H); 3.8 (s, 3H); 3.97 (m, 1H); 5.04 (m, 1H); 5.40 (s(br), 1H); 6.57 (d, 1H, J = 
2.2 Hz);7.08 (m, 1H); 7.69 (s(br), 1H); 7.92 (s, 1H); 12.9 (s(br), 1H). HRMS: calcd for 
C15H17N5O3S + H: 348.1130; found: 348.1185. 
Methyl 2-(4-(5-ethoxy-N-methyl-1H-pyrazole-3-carboxamido)-3,4-dihydropyridin-1(2H)-
yl)thiazole-5-carboxylate (20b): By using the procedure described above, this compound was 
obtained as a pale yellow powder (0.76 g, 30 %). 1H NMR (DMSO-d6 at 90 °C): 1.33 (t, 3H, 
J = 7.1 Hz); 2.13 (m, 2H); 2.98 (s, 3H); 3.81 (s, 3H); 3.96 (m, 2H); 4.16 (q, 2H, J = 7.1 Hz); 
5.01 (dd, 1H, J = 2.8, 8.3 Hz); 5.15 (s(br), 1H); 5.97 (s, 1H); 7.10 (d, 1H, J = 8.3 Hz); 7.92 (s, 
1H); 12.20 (s, 1H). HRMS: calcd for C17H21N5O4S + H: 392.1393; found: 392.1490. 
Methyl 2-(4-(4-chloro-N-methyl-1H-pyrazole-3-carboxamido)-3,4-dihydropyridin-1(2H)-
yl)thiazole-5-carboxylate (20c): By using the procedure described above, this compound was 
obtained, after a recrystallization in toluene, as a pale yellow powder still containing traces of 
toluene (0.53 g, 43 %). 1H NMR (DMSO-d6 at 90 °C): 2.15 (m, 2H); 2.90 (s, 3H); 3.69 (m, 
1H); 3.80 (s, 3H); 3.96 (m, 1H); 5.00 (m, 2H); 7.09 (m, 1H); 7.87 (s(br), 1H); 7.91 (s, 1H); 
13.99 (s, 1H). HRMS: calcd for C17H21N5O4S + H: 382.0706; found: 382.0741. 
General reduction of compounds 20a-c, representative synthesis of methyl 2-(4-(N-methyl-
1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylate (21a): Under a calcium 
chloride-protected atmosphere, to a solution of compound 20a (0.37 g, 1.06 mmol) in 
dichloromethane (50 mL) were added trifluoromethane sulfonic acid (0.47 mL, 5.33 mmol) 
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and triethylsilane (0.68 ml, 8.5 mmol). This was stirred overnight and concentrated to 
dryness. The residue was dissolved in ethyl acetate, the organic layer was washed with a 
saturated solution of sodium hydrogen carbonate, brine, dried over magnesium sulfate and 
concentrated to dryness. A chromatography over silica gel (dichloromethane – ethanol 97/3) 
gave compound 21a as a white powder (0.14 g, 38 %). 1H NMR (DMSO-d6 at 90 °C): 1.82 
(m, 2H); 1.91 (m, 2H); 2.98 (s, 3H); 3.19 (m, 2H); 3.77 (s, 3H); 4.10 (m, 2H); 4.62 (m, 1H); 
6.54 (d, 1H, J = 2.2 Hz); 7.76 (d, 1H, J = 2.2 Hz); 7.85 (s, 1H). HRMS: calcd for 
C15H19N5O3S + H: 350.1262; found: 350.1287. 
Methyl 2-(4-(3-ethoxy-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylate (21b): By using the procedure described above, compound 21b was obtained as 
glass (0.10 g, 22 %). 1H NMR (DMSO-d6 at 90 °C): 1.30 (t, 3H, J = 7.1 Hz); 1.80 (m, 2H); 
1.92 (m, 2H); 2.96 (s, 3H); 3.27 (m, 2H); 3.75 (s, 3H); 4.10 (m, 2H); 4.16 (q, 2H, J = 7.1 Hz); 
4.49 (m, 1H); 6.01 (s, 1H); 7.86 (s, 1H); 12.54 (s, 1H). HRMS: calcd for C17H23N5O4S + H: 
394.1549; found: 394.1569. Moreover, another chromatographic fraction contained a 
substance which was recrystallized in a mixture of cyclohexane and toluene to yield methyl 2-
(2-ethoxy-5-methyl-4-oxo-5,6,7,8-tetrahydro-4H-6,10-methanopyrazolo[1,5-
c][1,3,6]triazonin-9(10H)-yl)thiazole-5-carboxylate (22) as white crystals (0.08 g, 16 %). The 
use of HMQC and HMBC experiment allowed to following signals assignment. 1H NMR 
(DMSO-d6): 1.23 (t, J = 7.0 Hz, 3H, OCH2CH3); 1.95 (m, 2H, CH2-7); 2.54 (m, 1H, ½ CH-
CH2-CH); 2.66 (m, 1H, ½ CH-CH2-CH); 2.85 (m, 1H, ½ CH2-8); 3.08 (s, 3H, NMe); 3.78 (s, 
3H, OMe); 3.94 (m, 2H, CH-6 and ½ CH2-8); 4.03 (m, 2H, OCH2CH3); 6.39 (s, 1H,CH-3); 
6.49 (m, 1H,CH-10); 7.92 (s, 1H, CH-4 pyrazole). 13C NMR (DMSO-d6): 14.4 (OCH2CH3); 
27.0 (CH-CH2-CH); 30.0 (CH-7); 36.6 (N-CH3); 39.5 (CH-8); 51.6 (CH-6); 51.9 (OCH3); 
64.5 (OCH2CH3); 69.4 (CH-10); 98.2 (CH-3); 116.6 (C5’); 139.7 (C3a); 147.2 (CH-4’); 156.8 
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(C-4); 160.9 (C2); 161.5 (C2’); 172.7 (CO2Me). HRMS: calcd for C17H21N5O4S + H: 
392.1414; found: 392.1393. 
Methyl 2-(4-(4-chloro-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylate (21c): By using the procedure described above, this compound was obtained as a 
glass (0.07 g, 46 %). 1H NMR (DMSO-d6 at 90 °C): 1.86 (m, 4H); 2.87 (s, 3H); 3.18 (m, 2H); 
3.77 (s, 3H); 4.09 (m, 2H); 4.29 (s, 1H); 7.82 (s, 1H); 7.87 (s, 1H); 13.16 (s, 1H). HRMS: 
calcd for C15H18ClN5O3S + H: 384.0897; found: 384.0928. 
Alternative preparation of methyl 2-(4-(methylamino)piperidin-1-yl)thiazole-5-carboxylate 
(19): In a vial adapted for microwave heating, N-methylpiperidin-4-amine bishydrochloride 
(23) (1.0 g, 5.34 mmol), methyl 2-bromothiazole-5-carboxylate (16) (1.18 g, 5.34 mmol) and 
diisopropylethylamine (2.11 g, 16.29 mmol) were dissolved in dry acetonitrile (15 mL, dried 
over 4Å molecular sieve). This was heated in a microwave oven for 2 hours at 100 °C and the 
resulting mixture was concentrated to dryness. The residue was dispersed in brine, a saturated 
solution of sodium hydrogen carbonate and ethyl acetate. The aqueous layer was extracted 
four times with ethyl acetate, the organic layers were combined and washed once with brine, 
dried over sodium carbonate and concentrated to dryness to give an oil (0.79 g) which was 
used without further purification in the next step. An LC/MS analysis pointed out the 
occurrence of the expected m/z = 256 (compound 19) as well as, to a lesser degree, m/z = 397 
(compound 24). 
Preparation of compounds 21c-j representative synthesis of methyl 2-(4-(4-chloro-N-
methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylate (21c): The crude 
mixture containing compound 24 and 19 (0.28 g, 1.09 mmol), 4-chloro-1H-pyrazole-5-
carboxylic acid (11c) (0.16 g, 1.09 mmol), and diisopropylethylamine (0.59 g, 4.58mmol) 
were dissolved in dry tetrahydrofuran (30 mL, dried over 4Å molecular sieves). The O-
(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (0.74 g, 2.29 mmol) was 
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added and the suspension was stirred at room temperature under a calcium chloride-protected 
atmosphere overnight. Concentrated ammonia (10 mL, 22 %) was added and this was stirred 
for two hours. The resulting suspension was diluted in ethyl acetate and a saturated solution of 
sodium hydrogen carbonate. The organic layer was washed with water, brine, dried over 
magnesium sulfate and concentrated to dryness. In this specific case, the resulting residue was 
purified by two consecutive chromatography, the first one over silica gel (dichloromethane-
ethanol 95/5), the second one over alumina containing 1.5 % of water (dichloromethane-
ethanol 95/5) to yield compound 21c as a white foam (0.10 g, 9 % from N-methylpiperidin-4-
amine dihydrochloride (23)). The 1H NMR (DMSO-d6 at 90 °C) spectra was identical to the 
one reported above. 
Methyl 2-(4-(4-chloro-3-ethoxy-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-
yl)thiazole-5-carboxylate (21d): By following the protocol described above, a residue was 
obtained which was in this case purified by two consecutive chromatography, the first one 
over silica gel (dichloromethane-ethanol 97/3), the second one over alumina containing 1.5 % 
of water (dichloromethane-ethanol 96/4) to yield compound 21d as a glass (0.17 g, 16 % from 
N-methylpiperidin-4-amine dihydrochloride). 1H NMR (DMSO-d6 at 90 °C): 1.35 (t, 3H, J = 
7.2 Hz); 1.80 (m, 2H); 1.95 (m, 2H); 2.87 (s, 3H); 3.21 (m, 2H); 3.77 (s, 3H); 4.10 (m, 2H); 
4.23 (s(br), 1H); 4.27 (q, 2H, J = 7.2; Hz); 7.82 (s, 1H); 12.44 (s(br), 1H). HRMS: calcd for 
C17H22ClN5O4S + H: 428.1159; found: 428.1169. 
Methyl 2-(4-(N-methyl-3-propoxy-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylate (21e): By following the protocol described above, a residue was obtained which 
was in this case purified by two consecutive chromatography, the first one over silica gel 
(dichloromethane-ethanol from 97/3), the second one over alumina containing 1.5 % of water 
(dichloromethane-ethanol 96/4) to yield compound 21e as a glass (0.14 g, 14 % from N-
methylpiperidin-4-amine dihydrochloride). 1H NMR (DMSO-d6 at 90 °C): 0.98 (t, 3H, J = 
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7.5 Hz); 1.72 (m, 2H); 1.80 (m, 2H); 1.91 (m, 2H); 2.91 (s(br), 1/5 of 3H); 2.96 (s (br), 4/5 of 
3H); 3.24 (m, 2H); 3.77 (s, 3H); 4.08 (m, 4H); 4.42 (s(br), 4/5 of 1H); 4.67 (s(br), 1/5 of 1H); 
5.96 (s(br), 1H); 7.82 (s, 1H); 12.12 (s(br), 4/5 of 1H); 12.45 (s(br), 1/5 of 1H). HRMS: calcd 
for C18H25N5O4S + H: 408.1706; found: 408.1729. 
Methyl 2-(4-(3-butoxy-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylate (21f): By following the protocol described above, a residue was obtained which 
was in this case purified by two consecutive chromatography, the first one over silica gel 
(dichloromethane-ethanol from 97/3), the second one over alumina containing 1.5 % of water 
(dichloromethane-ethanol 96/4) to yield compound 21f as a glass (0.22 g, 18 % from N-
methylpiperidin-4-amine dihydrochloride). 1H NMR (DMSO-d6 at 90 °C): 0.95 (t, 3H, J = 
7.4 Hz); 1.45 (m, 2H); 1.71 (m, 2H); 1.81 (m, 2H); 1.92 (m, 2H); 2.95 (s(br), 3H); 3.24 (m, 
2H); 3.77 (s, 3H); 4.11 (m, 4H); 4.42 (s(br), 4/5 of 1H); 4.70 (s(br), 1/5 of 1H); 5.96 (s(br), 
1H); 7.82 (s, 1H); 12.13 (s(br), 4/5 of 1H); 12.46 (s(br), 1/5 of 1H). HRMS: calcd for 
C19H27N5O4S + H: 422.1862; found: 422.1879. 
Methyl 2-(4-(3-isopropoxy-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylate (21g): By following the protocol described above, a residue was obtained which 
was in this case purified by two consecutive chromatography, the first one over silica gel 
(dichloromethane-ethanol from 97/3 to 96/4), the second one over alumina containing 1.5 % 
of water (dichloromethane-ethanol 96/4) to yield compound 21g as a glass (0.26 g, 21 % from 
N-methylpiperidin-4-amine dihydrochloride). 1H NMR (DMSO-d6 at 90 °C): 1.30 (d, 6H, J = 
6.1 Hz); 1.80 (m, 2H); 1.91 (m, 2H); 2.92 (s(br), 1/6 of 3H); 2.96 (s (br), 5/6 of 3H); 3.23 (m, 
2H); 3.78 (s, 3H); 4.10 (m, 2H); 4.44 (s(br), 1H); 4.68 (s(br), 1H); 5.93 (s(br), 1H); 7.82 (s, 
1H); 12.13 (s(br), 5/6 of 1H); 12.43 (s(br), 1/6 of 1H). HRMS: calcd for C18H25N5O4S + H: 
408.1706; found: 408.1739. 
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Methyl 2-(4-(N-methyl-3-(pentan-3-yloxy)-1H-pyrazole-5-carboxamido)piperidin-1-
yl)thiazole-5-carboxylate (21h): By following the protocol described above, a residue was 
obtained which was in this case purified by two consecutive chromatography, the first one 
over silica gel (dichloromethane-ethanol from 97/3), the second one over alumina containing 
1.5 % of water (dichloromethane-ethanol 96/4) to yield compound 21h as a glass (0.30 g, 26 
% from N-methylpiperidin-4-amine dihydrochloride). 1H NMR (DMSO-d6 at 90 °C): 0.93 (t, 
6H, J = 7.6 Hz); 1.66 (m, 4H); 1.80 (m, 2H); 1.91 (m, 2H); 2.92 (s(br), 1/6 of 3H); 2.96 (s 
(br), 5/6 of 3H); 3.23 (m, 2H); 3.77 (s, 3H); 4.10 (m, 2H); 4.35 (s(br), 1H); 4.43 (s(br), 1H); 
5.95 (s(br), 1H); 7.82 (s, 1H); 12.09 (s(br), 5/6 of 1H); 12.42 (s(br), 1/6 of 1H). HRMS: calcd 
for C20H29N5O4S + H: 436.2019; found: 436.2049. 
Methyl 2-(4-(4-bromo-N,3-dimethyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylate (21i): By following the protocol described above, a residue was obtained which 
was in this case purified by two consecutive chromatography, the first one over silica gel 
(dichloromethane-ethanol 95/5), the second one over alumina containing 1.5 % of water 
(dichloromethane-ethanol 95/5) to yield compound 21i as a glass (0.18 g, 15 % from N-
methylpiperidin-4-amine dihydrochloride). 1H NMR (DMSO-d6 at 90 °C): 1.80 (m, 2H); 1.92 
(m, 2H); 2.24 (s, 3H); 2.86 (s, 3H); 3.23 (m, 2H); 3.77 (s, 3H); 4.10 (m, 2H); 4.29 (s(br), 1H); 
7.82 (s, 1H); 12.90 (s(br), 1H). HRMS: calcd for C16H20BrN5O3S + H: 442.0548; found: 
442.0555. 
Methyl 2-(4-(4-bromo-N-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamido)piperidin-
1-yl)thiazole-5-carboxylate (21j): By following the protocol described above, a residue was 
obtained which was in this case purified by a chromatography over silica gel 
(dichloromethane-ethanol 96/4) followed by a dispersion in boiling toluene which led to pure 
compound 21j (0.26 g, 19 % from N-methylpiperidin-4-amine dihydrochloride) as a white 
powder. 1H NMR (DMSO-d6 at 90 °C): 1.81 (m, 2H); 1.97 (m, 2H); 2.87 (s, 3H); 3.23 (m, 
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2H); 3.77 (s, 3H); 4.10 (m, 2H); 4.23 (s(br), 1H); 7.82 (s, 1H); 14.31 (s, 1H). HRMS: calcd 
for C16H17BrF3N5O3S + H: 496.0266; found: 496.0331. 
2-(4-(N-Methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic acid (9a): 
Compound 21a (0.11 g, 0.32 mmol) and lithium hydroxide (0.13 g, 3.1 mmol) were stirred in 
water (10 mL) and tetrahydrofuran (30 mL) overnight. This was concentrated to dryness, 
made acidic with hydrochloric acid and, since there was no precipitate in these cases, the 
aqueous phase was extracted with ethyl acetate five times. The organic layers were combined 
and washed with brine once, dried over magnesium sulfate and concentrated to dryness to 
yield compound 9a as a white powder (0.01 g, 10 %). 1H NMR (DMSO-d6 at 90 °C): 1.91 
(m, 4H); 2.99 (s, 3H); 3.18 (m, 2H); 4.10 (m, 2H); 4.62 (m, 1H); 6.55 (d, 1H, J = 2.2 Hz); 
7.67 (d, 1H, J = 2.2 Hz); 7.75 (s 1H); 12.88 (s, 1H). HRMS: calcd for C14H17N5O3S + H: 
336.1130; found: 336.1145. 
2-(4-(3-Ethoxy-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic 
acid (9b): By using the procedure described above, this compound was obtained as a pale 
yellow powder (0.06 g, 89 %). 1H NMR (DMSO-d6 at 90 °C): 1.33 (t, 3H, J = 7.1 Hz); 1.91 
(m, 4H); 2.96 (s, 3H); 3.21 (m, 2H); 4.09 (m, 2H); 4.16 (q, 2H, J = 7.1 Hz); 4.48 (m, 1H); 
5.94 (s, 1H); 7.76 (s, 1H); 12.58 (s, 1H). HRMS: calcd for C16H21N5O4S + H: 380.1393; 
found: 380.1395. 
2-(4-(4-Chloro-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic 
acid (9c): By using the procedure described above, this compound was obtained as a white 
powder (0.04 g, 59 %). 1H NMR (DMSO-d6 at 90 °C?) 1.81 (m, 2H); 1.90 (m, 2H); 2.86 (s, 
3H); 3.15 (m, 2H); 4.08 (m, 2H); 4.27 (s(br), 1H); 7.74 (s, 1H); 7.83 (s, 1H). HRMS: calcd for 
C14H16ClN5O3S + H: 370.0741; found: 370.0741. 
2-(4-(4-chloro-3-ethoxy-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylic acid (9d): Compound 21d (0.15 g, 0.35 mmol), lithium hydroxide (0.15 g, 3.5 
Page 33 of 40
https://mc06.manuscriptcentral.com/cjc-pubs
Canadian Journal of Chemistry
Draft
34 
 
mmol) were stirred in water (5 mL) and tetrahydrofuran (10 mL) overnight. This was 
concentrated to dryness. The residue was dissolved in a small amount of water saturated with 
sodium chloride and made acid with the minimum amount of 1N hydrochloric acid. The 
resulting suspension was extracted with ethyl acetate, the organic layer was washed with 
brine, dried over magnesium sulfate and concentrated to dryness. The residue was dispersed 
in a small amount of water, this was filtered and dried to give compound 9d as a white 
powder (0.11 g, 75 %). 1H NMR (DMSO-d6 at 90 °C): 1.35 (t, 3H, J = 7.1 Hz); 1.81 (m, 2H); 
1.92 (m, 2H); 2.87 (s, 3H); 3.18 (m, 2H); 4.08 (m, 2H); 4.22 (s(br), 1H); 4.27 (q, 2H, J = 7.1; 
Hz); 7.74 (s, 1H); 12.28 (s(br), 1H). HRMS: calcd for C16H20ClN5O4S + H: 414.1003; found: 
414.1021. 
2-(4-(N-methyl-3-propoxy-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic 
acid (9e): Compound 21e (0.12 g, 0.29 mmol), lithium hydroxide (0.12 g, 2.8 mmol) were 
stirred in water (5 mL) and tetrahydrofuran (10 mL) overnight. This was concentrated to 
dryness. The residue was dissolved in a small amount of water saturated with sodium chloride 
and made acid with the minimum amount of 1N hydrochloric acid. The resulting suspension 
was extracted with ethyl acetate, the organic layer was washed with brine, dried over 
magnesium sulfate and concentrated to dryness to yield compound 9e as a white powder (0.07 
g, 60 %). 1H NMR (DMSO-d6 at 90 °C): 0.94 (t, 3H, J = 7.4 Hz); 1.73 (m, 2H); 1.80 (m, 2H); 
1.91 (m, 2H); 2.96 (s, 3H); 3.20 (m, 2H); 4.06 (t, 2H, J = 6.6 Hz); 4.09 (m, 2H); 4.48 (m, 1H); 
5.94 (s, 1H); 7.75 (s, 1H); 12.16 (s(br), 1H). HRMS: calcd for C17H23N5O4S + H: 394.1549; 
found: 394.1538. 
2-(4-(3-butoxy-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-carboxylic 
acid (9f): Compound 21f (0.2 g, 0.47 mmol), lithium hydroxide (0.2 g, 4.7 mmol) were stirred 
in water (5 mL) and tetrahydrofuran (10 mL) overnight. This was concentrated to dryness. 
The residue was dissolved in a small amount of water saturated with sodium chloride and 
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made acid with the minimum amount of 1N hydrochloric acid. The resulting suspension was 
extracted with ethyl acetate, the organic layer was washed with brine, dried over magnesium 
sulfate and concentrated to dryness to yield compound 9f as a white powder (0.09 g, 46 %). 
1H NMR (DMSO-d6 at 90 °C): 0.94 (t, 3H, J = 7.3 Hz); 1.44 (m, 2H); 1.70 (m, 2H); 1.79 (m, 
2H); 1.91 (m, 2H); 2.96 (s, 3H); 3.21 (m, 2H); 4.09 (m, 2H); 4.10 (t, 2H, J = 6.6 Hz); 4.48 (m, 
1H); 5.94 (s, 1H); 7.75 (s, 1H); 11.80 (s(br), 1H). HRMS: calcd for C18H25N5O4S + H: 
408.1706; found: 408.1734. 
2-(4-(3-isopropoxy-N-methyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylic acid (9g): Compound 21g (0.24 g, 0.58 mmol), lithium hydroxide (0.24 g, 5.7 
mmol) were stirred in water (5 mL) and tetrahydrofuran (10 mL) overnight. This was 
concentrated to dryness. The residue was dissolved in a small amount of water saturated with 
sodium chloride and made acid with the minimum amount of 1N hydrochloric acid. The 
resulting suspension was extracted with ethyl acetate, the organic layer was washed with 
brine, dried over magnesium sulfate and concentrated to dryness to yield compound 9g as a 
white powder (0.13 g, 56 %). 1H NMR (DMSO-d6 at 90 °C): 1.30 (d, 6H, J = 6.3 Hz); 1.80 
(m, 2H); 1.91 (m, 2H); 2.96 (s, 3H); 3.20 (m, 2H); 4.08 (m, 2H); 4.48 (m, 1H); 4.63 (sept, 1H, 
J = 6.3 Hz); 5.92 (s, 1H); 7.75 (s, 1H); 12.02 (s(br), 1H). HRMS: calcd for C17H23N5O4S + H: 
394.1549; found: 394.1562. 
2-(4-(N-methyl-3-(pentan-3-yloxy)-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylic acid (9h): Compound 21h (0.28 g, 0.64 mmol), lithium hydroxide (0.28 g, 6.6 
mmol) were stirred in water (5 mL) and tetrahydrofuran (10 mL) overnight. This was 
concentrated to dryness. The residue was dissolved in a small amount of water saturated with 
sodium chloride and made acid with the minimum amount of 1N hydrochloric acid. The 
resulting suspension was dispersed in ethyl acetate and this now biphasic suspension was 
filtered, washed with water and ethyl acetate and dried under vacuum to yield compound 9h 
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as a white powder (0.19 g, 70 %). 1H NMR (DMSO-d6 at 90 °C): 0.92 (t, 6H, J = 7.2 Hz); 
1.65 (m, 4H); 1.74 (m, 2H); 1.89 (m, 2H); 2.95 (s(br), 1H); 3.0 (m, 2H); 4.01 (m, 2H); 4.27 
(pent, 1H, J = 5.8 Hz); 4.43 (m, 1H); 5.90 (s, 1H); 7.26 (s, 1H); 12.24 (s(br), 1H). HRMS: 
calcd for C19H27N5O4S + H: 422.1862; found: 422.1862. 
2-(4-(4-Bromo-N,3-dimethyl-1H-pyrazole-5-carboxamido)piperidin-1-yl)thiazole-5-
carboxylic acid (9i): Compound 21i (0.13 g, 0.29 mmol), lithium hydroxide (0.12 g, 2.8 
mmol) were stirred in water (10 mL) and tetrahydrofuran (30 mL) overnight. This was 
concentrated to dryness. The residue was dissolved in a small amount of water and made acid 
with the minimum amount of 1N hydrochloric acid. The resulting precipitate was filtered and 
dried under vacuum at 50 °C to yield acid 9i as a white powder (0.06 g, 47 %). 1H NMR 
(DMSO-d6 at 90 °C): 1.80 (m, 2H); 1.92 (m, 2H); 2.23 (s, 3H); 2.85 (s, 3H); 3.15 (m, 2H); 
4.07 (m, 2H); 4.28 (s(br), 1H); 7.74 (s, 1H). HRMS: calcd for C15H18BrN5O3S + H: 428.0392; 
found: 428.0397. 
2-(4-(4-Bromo-N-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamido)piperidin-1-
yl)thiazole-5-carboxylic acid (9j): By following the protocol described above, this acid was 
obtained as a white powder (0.14 g, 72 %). 1H NMR (DMSO-d6 at 90 °C): 1.80 (m, 2H); 1.95 
(m, 2H); 2.87 (s, 3H); 3.20 (m, 2H); 4.10 (m, 2H); 4.22 (s(br), 1H); 7.75 (s, 1H). HRMS: 
calcd for C15H15BrF3N5O3S + H: 482.0109; found: 482.0146. 
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